You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • AB0423 Nobility, A Phase 2 Trial To Assess The Safety and Efficacy of Obinutuzumab, A Novel Type 2 Anti-CD20 Monoclonal Antibody (MAB), in Patients (PTS) with ISN/RPS Class III or IV Lupus Nephritis (LN)

Article metrics

Article menu
Download PDFPDF
Abstracts Accepted for Publication
SLE, Sjögren's and APS - treatment
AB0423 Nobility, A Phase 2 Trial To Assess The Safety and Efficacy of Obinutuzumab, A Novel Type 2 Anti-CD20 Monoclonal Antibody (MAB), in Patients (PTS) with ISN/RPS Class III or IV Lupus Nephritis (LN)

 

Online download statistics by month:

Online download statistics by month: July 2016 to March 2024

AbstractFullPdf
Jul 2016805
Aug 2016501
Sep 201615014
Oct 201611011
Nov 20162205
Dec 20161301
Jan 20172100
Feb 20171904
Mar 20172002
Apr 20172505
May 20171701
Jun 20171902
Jul 20172603
Aug 20173000
Sep 20173001
Oct 20174205
Nov 20178802
Dec 20171000
Jan 20181800
Feb 20181400
Mar 20182200
Apr 20184402
May 20184200
Jun 20183600
Jul 20181801
Aug 20183200
Sep 20182401
Oct 20182600
Nov 20181600
Dec 20182201
Jan 20193800
Feb 20192800
Mar 20193101
Apr 20194605
May 20195803
Jun 2019196018
Jul 2019112011
Aug 201913005
Sep 2019456027
Oct 2019284012
Nov 2019417016
Dec 2019294012
Jan 2020316019
Feb 2020246013
Mar 2020990013
Apr 202011005
May 2020178017
Jun 2020186016
Jul 202011907
Aug 202018205
Sep 202018208
Oct 202030004
Nov 2020386013
Dec 202021104
Jan 2021254011
Feb 202122408
Mar 202139408
Apr 202123406
May 20217906
Jun 2021003
Jul 2021509
Aug 2021304
Sep 20217012
Oct 202118409
Nov 202114106
Dec 20213102
Jan 20226503
Feb 20224601
Mar 20227300
Apr 20223800
May 20223501
Jun 20222602
Jul 20223801
Aug 20223002
Sep 20224403
Oct 20228803
Nov 20228101
Dec 20224200
Jan 20239201
Feb 20235003
Mar 20235803
Apr 20235201
May 20232601
Jun 20233501
Jul 20232000
Aug 20232603
Sep 20234002
Oct 20231400
Nov 20234802
Dec 20234000
Jan 20244202
Feb 20243701
Mar 20242800
Total90010422